

Ewa Janczewska

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4984200/publications.pdf>

Version: 2024-02-01

65
papers

1,846
citations

567281
15
h-index

265206
42
g-index

65
all docs

65
docs citations

65
times ranked

2415
citing authors

#	ARTICLE	IF	CITATIONS
1	ABT-450/râ€“Ombitasvir and Dasabuvir with or without Ribavirin for HCV. New England Journal of Medicine, 2014, 370, 1983-1992.	27.0	669
2	Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naïve patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet, The, 2014, 384, 414-426.	13.7	376
3	Seladelpar (MBX-8025), a selective PPAR-Î³ agonist, in patients with primary biliary cholangitis with an inadequate response to ursodeoxycholic acid: a double-blind, randomised, placebo-controlled, phase 2, proof-of-concept study. The Lancet Gastroenterology and Hepatology, 2017, 2, 716-726.	8.1	126
4	Realâ€“world effectiveness and safety of ombitasvir/paritaprevir/ritonavirÂ±Â±Â±dasabuvirÂ±Â±Â±ribavirin in hepatitis C: AMBER study. Alimentary Pharmacology and Therapeutics, 2016, 44, 946-956.	3.7	82
5	Efficacy and safety of ombitasvir/paritaprevir/r and dasabuvir compared to IFN-containing regimens in genotype 1 HCV patients: The MALACHITE-I/II trials. Journal of Hepatology, 2016, 64, 19-28.	3.7	60
6	Telaprevir Twice Daily Is Noninferior to Telaprevir Every 8 Hours for Patients With Chronic Hepatitis C. Gastroenterology, 2014, 146, 744-753.e3.	1.3	42
7	Efficacy of Immunotherapy With TG4040, Peg-Interferon, and Ribavirin in a Phase 2 Study of Patients With Chronic HCV Infection. Gastroenterology, 2014, 147, 119-131.e3.	1.3	30
8	Bioinformatics analysis of key genes and pathways for hepatocellular carcinoma transformed from cirrhosis. Medicine (United States), 2017, 96, e6938.	1.0	29
9	Visfatin serum levels in chronic hepatitis C patients. Journal of Viral Hepatitis, 2010, 17, 254-260.	2.0	26
10	TGF-beta1 mRNA expression in liver biopsy specimens and TGF-beta1 serum levels in patients with chronic hepatitis C before and after antiviral therapy. Journal of Clinical Pharmacy and Therapeutics, 2005, 30, 271-277.	1.5	25
11	Effectiveness and safety of ledipasvir/sofosbuvir Â± ribavirin in the treatment of HCV infection: The real-world HARVEST study. Advances in Medical Sciences, 2017, 62, 387-392.	2.1	23
12	Treatment of <scp>HCV</scp> infection in Poland at the beginning of the interferonâ€“free eraâ€“the EpiTerâ€“2 study. Journal of Viral Hepatitis, 2018, 25, 661-669.	2.0	22
13	Durability of virologic response, risk of de novo hepatocellular carcinoma, liver function and stiffness 2Â±years after treatment with ombitasvir/paritaprevir/ritonavirÂ±dasabuvirÂ±ribavirin in the AMBER, realâ€“world experience study. Journal of Viral Hepatitis, 2018, 25, 1298-1305.	2.0	19
14	Prevalence of HCV genotypes in Poland â€“ the EpiTer study. Clinical and Experimental Hepatology, 2016, 4, 144-148.	1.3	18
15	Effect of interferon alpha and ribavirin treatment on serum levels of transforming growth factor-Î²1, vascular endothelial growth factor, and basic fibroblast growth factor in patients with chronic hepatitis C. World Journal of Gastroenterology, 2006, 12, 961.	3.3	18
16	Daclatasvir<i>vs</i>telaprevir plus peginterferon alfa/ribavirin for hepatitis C virus genotype 1. World Journal of Gastroenterology, 2016, 22, 3418-3431.	3.3	17
17	Efficacy of HCV treatment in Poland at the turn of the interferon era â€“ the EpiTer study. Clinical and Experimental Hepatology, 2016, 4, 138-143.	1.3	16
18	Five-Year Follow-Up of Cured HCV Patients under Real-World Interferon-Free Therapy. Cancers, 2021, 13, 3694.	3.7	16

#	ARTICLE	IF	CITATIONS
19	Changes of patient profile, treatment effectiveness and safety during 4 years access to interferon-free therapy for hepatitis C virus infection. Polish Archives of Internal Medicine, 2020, 130, 163-172.	0.4	14
20	Effectiveness and Safety of Pangenotypic Regimens in the Most Difficult to Treat Population of Genotype 3 HCV Infected Cirrhotics. Journal of Clinical Medicine, 2021, 10, 3280.	2.4	13
21	Real World Experience of Chronic Hepatitis C Retreatment with Genotype Specific Regimens in Nonresponders to Previous Interferon-Free Therapy. Canadian Journal of Gastroenterology and Hepatology, 2019, 2019, 1-9.	1.9	12
22	Real life results of direct acting antiviral therapy for HCV infection in HIV+HCV-coinfected patients: Epi-Ter2 study. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2020, 32, 762-769.	1.2	12
23	Low risk of HBV reactivation in a large European cohort of HCV/HBV coinfectd patients treated with DAA. Expert Review of Anti-Infective Therapy, 2020, 18, 1045-1054.	4.4	12
24	Acromegaly and the risk of cancer. Pathophysiology, 2001, 8, 69-75.	2.2	10
25	61 FACTORS INFLUENCING PROGRESSION OF LIVER FIBROSIS IN PATIENTS WITH CHRONIC HEPATITIS C: RESULTS OF THE 3-YEAR T2S-918-HCV STUDY WITH HCVE1 THERAPEUTIC VACCINATION. Journal of Hepatology, 2008, 48, S27-S28.	3.7	10
26	Effect of Peginterferon or Ribavirin Dosing on Efficacy of Therapy With Telaprevir in Treatment-Experienced Patients With Chronic Hepatitis C and Advanced Liver Fibrosis. Medicine (United States), 2017, 96, e7275.	1.0	10
27	China's growing contribution to sepsis research from 1984 to 2014. Medicine (United States), 2017, 96, e7275.	1.0	10
28	Real-world effectiveness and safety of direct-acting antivirals in patients with cirrhosis and history of hepatic decompensation: Epi-Ter2 Study. Liver International, 2021, 41, 1789-1801.	3.9	10
29	sPECAM-1 and sVCAM-1: role in pathogenesis and diagnosis of chronic hepatitis C and association with response to antiviral therapy. Therapeutic Advances in Gastroenterology, 2009, 2, 79-90.	3.2	9
30	Is Interferon-Based Treatment of Viral Hepatitis C Genotype 3 Infection Still of Value in the Era of Direct-Acting Antivirals?. Journal of Interferon and Cytokine Research, 2018, 38, 93-100.	1.2	9
31	Real-world experience with Grazoprevir/Elbasvir in the treatment of previously "difficult to treat" patients infected with hepatitis C virus genotype 1 and 4. Journal of Gastroenterology and Hepatology (Australia), 2020, 35, 1238-1246.	2.8	9
32	Is an 8-week regimen of glecaprevir/pibrentasvir sufficient for all hepatitis C virus infected patients in the real-world experience?. Journal of Gastroenterology and Hepatology (Australia), 2020, 36, 1944-1952.	2.8	9
33	Immunogenicity, Safety, and Tolerability of V114, a 15-Valent Pneumococcal Conjugate Vaccine, in Immunocompetent Adults Aged 18-49 Years With or Without Risk Factors for Pneumococcal Disease: A Randomized Phase 3 Trial (PNEU-DAY). Open Forum Infectious Diseases, 2022, 9, ofab605.	0.9	9
34	P0847 : Malachite-II: Phase 3b trial of ombitasvir/paritaprevir/r and dasabuvir + ribavirin or telaprevir + peginterferon/ribavirin in peginterferon/ribavirin treatment-experienced adults with HCV genotype 1. Journal of Hepatology, 2015, 62, S656-S657.	3.7	8
35	798 EFFICACY OF TELAPREVIR DOSED TWICE DAILY VERSUS EVERY 8 HOURS BY IL28B GENOTYPE: RESULTS FROM THE PHASE III OPTIMIZE STUDY. Journal of Hepatology, 2013, 58, S326.	3.7	7
36	1403 SIGNIFICANT IMPROVEMENT OF COMPLETE EVR IN HCVAC PHASE II CLINICAL TRIAL WHEN ADDING TG4040 THERAPEUTIC VACCINE TO PEGIFN-2A AND RIBAVIRIN. Journal of Hepatology, 2012, 56, S552.	3.7	6

#	ARTICLE	IF	CITATIONS
37	P1299 PEARL-III: 12 WEEKS OF ABT-450/R/267 + ABT-333 ACHIEVED SVR IN >99% OF 419 TREATMENT-NAIVE HCV GENOTYPE 1B-INFECTED ADULTS WITH OR WITHOUT RIBAVIRIN. <i>Journal of Hepatology</i> , 2014, 60, S527.	3.7	6
38	Hepatitis C virus (HCV) genotype 1 NS5A resistance-associated variants are associated with advanced liver fibrosis independently of HCV-transmission clusters. <i>Clinical Microbiology and Infection</i> , 2019, 25, 513.e1-513.e6.	6.0	6
39	JN4178 (AL335, Odalasvir, and Simeprevir) for 6 or 8 Weeks in Hepatitis C Virus-Infected Patients Without Cirrhosis: OMEGA1. <i>Hepatology</i> , 2019, 69, 2349-2363.	7.3	6
40	Comparative effectiveness of 8 versus 12 weeks of Ombitasvir/Paritaprevir/ritonavir and Dasabuvir in treatment-naïve patients infected with HCV genotype 1b with non-advanced hepatic fibrosis. <i>Advances in Medical Sciences</i> , 2020, 65, 12-17.	2.1	5
41	Factors influencing the failure of interferon-free therapy for chronic hepatitis C: Data from the Polish EpiTer-2 cohort study. <i>World Journal of Gastroenterology</i> , 2021, 27, 2177-2192.	3.3	5
42	905 ADHERENCE WITH TELAPREVIR BID vs. q8h DOSING IN TREATMENT-NAIVE HCV-INFECTED PATIENTS: RESULTS FROM THE PHASE III OPTIMIZE STUDY. <i>Journal of Hepatology</i> , 2013, 58, S373.	3.7	3
43	P0842 : Malachite-I: Phase 3B Trial of ombitasvir/paritaprevir/r and dasabuvir +/â~ ribavirin or telaprevir + peginterferon/ribavirin in treatment-naïve adults with HCV genotype 1. <i>Journal of Hepatology</i> , 2015, 62, S653-S654.	3.7	2
44	The efficacy of paritaprevir/ritonavir/ombitasvir+dasabuvir and ledipasvir/sofosbuvir is comparable in patients who failed interferon-based treatment with first generation protease inhibitors - a multicenter cohort study. <i>BMC Infectious Diseases</i> , 2018, 18, 580.	2.9	2
45	Efficacy of 8- versus 12-week treatment with ledipasvir/sofosbuvir in chronic hepatitis C patients eligible for 8 week regimen in a real-world setting. <i>Archives of Medical Science</i> , 2019, , .	0.9	2
46	HCV resistance-associated substitutions following direct-acting antiviral therapy failure â€œ Real-life data from Poland. <i>Infection, Genetics and Evolution</i> , 2021, 93, 104949.	2.3	2
47	Real-world direct-acting antiviral treatment in kidney transplant and hemodialysis patients: the EpiTer-2 multicenter observational study. <i>Annals of Gastroenterology</i> , 2021, 34, 438-446.	0.6	2
48	Interferon Free Therapy with and Without Ribavirin for Genotype 1 HCV Cirrhotic Patients in the Real World Experience. <i>Hepatitis Monthly</i> , 2018, 18, .	0.2	2
49	Pangenotypic and Genotype-Specific Antivirals in the Treatment of HCV Genotype 4 Infected Patients with HCV Mono-infection and HIV/HCV Coinfection. <i>Journal of Clinical Medicine</i> , 2022, 11, 389.	2.4	2
50	Significant Decrease in the Prevalence of Anxiety and Depression after Hepatitis C Eradication. <i>Journal of Clinical Medicine</i> , 2022, 11, 3044.	2.4	2
51	816 RIBAVIRIN DOSE REDUCTION DURING TELAPREVIR CONTAINING TRIPLE THERAPY DOES NOT AFFECT EARLY VIROLOGIC RESPONSE IN NON-RESPONDERS AND RELAPERS WITH ADVANCED LIVER FIBROSIS. <i>Journal of Hepatology</i> , 2013, 58, S334-S335.	3.7	1
52	P1169 EFFECT OF PEGYLATED INTERFERON OR RIBAVIRIN DOSE REDUCTION DURING TELAPREVIR BASED THERAPY ON SVR12 IN NULL-RESPONDERS AND RELAPERS WITH ADVANCED LIVER FIBROSIS (ADVEX STUDY). <i>Journal of Hepatology</i> , 2014, 60, S474.	3.7	1
53	Simeprevir with peginterferon 1a/2a/ribavirin for chronic hepatitis C virus genotype 1 infection in treatment-experienced patients: an open-label, rollover study. <i>BMC Infectious Diseases</i> , 2017, 17, 389.	2.9	1
54	THU-217-Low risk of HBV reactivation in a large European cohort of HBV/ HCV coinfecting patients treated with DAA. <i>Journal of Hepatology</i> , 2019, 70, e259.	3.7	1

#	ARTICLE	IF	CITATIONS
55	Effect of comedication on ombitasvir/paritaprevir/ritonavir ± dasabuvir ± ribavirin therapy in chronic hepatitis C – a real-world study. Clinical and Experimental Hepatology, 2019, 5, 215-223.	1.3	1
56	1050. Phase 3 Trial to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by 23valent Pneumococcal Polysaccharide Vaccine 6 Months Later in At-risk Adults Aged 18–49 Years (PNEU-DAY): A Subgroup Analysis by Baseline Risk Factors. Open Forum Infectious Diseases, 2021, 8, S616-S617.	0.9	1
57	919 ANEMIA AND ITS MANAGEMENT IN PATIENTS TREATED WITH TELAPREVIR TWICE DAILY VERSUS EVERY 8 HOURS IN THE PHASE III OPTIMIZE STUDY. Journal of Hepatology, 2013, 58, S379.	3.7	0
58	826 SAFETY AND EFFICACY OF TWICE DAILY VERSUS EVERY 8 HOUR TELAPREVIR WITH PEGINTERFERON/RIBAVIRIN (PR) IN PATIENTS WITH CIRRHOSIS. Journal of Hepatology, 2013, 58, S338-S339.	3.7	0
59	868 TREATMENT WITH TELAPREVIR-BASED THERAPY AFTER EXPOSURE TO PEG-IFN/RBV IN THE REALIZE STUDY: RESULTS FROM THE PHASE IIIB C219 ROLLOVER STUDY. Journal of Hepatology, 2013, 58, S356-S357.	3.7	0
60	P1209 FACTORS INFLUENCING RENAL FUNCTION IN PATIENTS RECEIVING TELAPREVIR TWICE DAILY OR EVERY 8 HOURS: RESULTS FROM THE PHASE III OPTIMIZE STUDY. Journal of Hepatology, 2014, 60, S491.	3.7	0
61	The efficacy of paritaprevir/ritonavir/ombitasvir + dasabuvir and ledipasvir/sofosbuvir is similar in patients who failed interferon-based treatment with first generation protease inhibitors. Journal of Hepatology, 2018, 68, S277.	3.7	0
62	Real world experience with twelve weeks of therapy without ribavirin in genotype 1 HCV infected compensated cirrhotics. Journal of Hepatology, 2018, 68, S296-S297.	3.7	0
63	THU-197-Comparative effectiveness of 8 versus 12 weeks of ombitasvir/paritaprevir/ritonavir and dasabuvir in treatment-naïve patients infected with HCV genotype 1b with non-advanced hepatic fibrosis. Journal of Hepatology, 2019, 70, e250.	3.7	0
64	THU-185-Effectiveness and safety of DAA-based treatment of hepatitis C patients with severe and end stage chronic kidney diseases-EpiTer-2 database analysis. Journal of Hepatology, 2019, 70, e243-e244.	3.7	0
65	THU-196-Efficacy of 8 versus 12-weeks treatment with ledipasvir/sofosbuvir in chronic hepatitis C patients eligible for 8-weeks regimen in real world setting. Journal of Hepatology, 2019, 70, e249-e250.	3.7	0